Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
SSY Group ( (HK:2005) ) has shared an announcement.
SSY Group Limited has received approvals from the National Medical Products Administration of China for the production and registration of new pharmaceutical products, including Dapagliflozin and Metformin Hydrochloride Sustained-release Tablets and Ibuprofen Arginine Granules. These developments are expected to enhance the company’s product offerings in diabetes management and pain relief. Additionally, the company has obtained registration approvals for Acipimox and Diprophylline as bulk drugs, which will support their market presence in treating hyperlipidemia and respiratory conditions.
More about SSY Group
SSY Group Limited operates in the pharmaceutical industry, focusing on the development and production of chemical drugs. The company’s primary products include medications for diabetes management, pain relief, and respiratory conditions, with a market focus on China.
YTD Price Performance: -11.86%
Technical Sentiment Signal: Buy
Current Market Cap: $1.13B
See more insights into 2005 stock on TipRanks’ Stock Analysis page.